Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 2
1961 2
1962 9
1963 18
1964 43
1965 53
1966 42
1967 41
1968 48
1969 46
1970 54
1971 40
1972 53
1973 68
1974 75
1975 66
1976 55
1977 55
1978 63
1979 59
1980 81
1981 48
1982 79
1983 63
1984 63
1985 64
1986 54
1987 55
1988 48
1989 76
1990 78
1991 61
1992 52
1993 53
1994 62
1995 67
1996 48
1997 43
1998 46
1999 64
2000 75
2001 77
2002 82
2003 71
2004 62
2005 64
2006 74
2007 57
2008 45
2009 39
2010 34
2011 36
2012 39
2013 33
2014 21
2015 25
2016 27
2017 15
2018 22
2019 26
2020 25
2021 30
2022 34
2023 24
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

3,055 results

Results by year

Filters applied: . Clear all
Page 1
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
Syed YY. Syed YY. Drugs. 2022 Oct;82(15):1549-1556. doi: 10.1007/s40265-022-01790-4. Epub 2022 Nov 4. Drugs. 2022. PMID: 36331779 Free PMC article. Review.
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate (Ryeqo(); Myfembree()) has been approved for the management of heavy menstrual bleeding associated with uterine fibroids in the USA and management of mo …
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate (Ryeqo(); My …
Relugolix, Estradiol, and Norethindrone Acetate.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2021 Sep 22;78(19):1755-1760. doi: 10.1093/ajhp/zxab268. Am J Health Syst Pharm. 2021. PMID: 34286333 No abstract available.
Efficacy and safety of ultra-low-dose estradiol and norethisterone in postmenopausal Brazilian women.
Bonassi Machado R, Pompei LM, Nahas EAP, Nahas-Neto J, Costa-Paiva LD, Del Debbio SYO, Badalotti M, Wender MCO, Cruz AM. Bonassi Machado R, et al. Climacteric. 2023 Aug;26(4):401-407. doi: 10.1080/13697137.2023.2190507. Epub 2023 Mar 28. Climacteric. 2023. PMID: 36977423
OBJECTIVE: This study aimed to evaluate the efficacy and safety of oral ultra-low-dose continuous combination of 17beta-estradiol (17beta-E2) and norethisterone acetate (NETA) in postmenopausal Brazilian women. ...
OBJECTIVE: This study aimed to evaluate the efficacy and safety of oral ultra-low-dose continuous combination of 17beta-estradiol (17 …
Trisequens.
[No authors listed] [No authors listed] Drug Ther Bull. 1981 Jul 31;19(16):63-4. Drug Ther Bull. 1981. PMID: 7274066 No abstract available.
Effects of estradiol, progestogens, and of tibolone on breast proliferation and apoptosis.
Pompei LM, Cunha EP, Steiner ML, Theodoro TR, Mader AM, Petri G, Pinhal MA, Fernandes CE. Pompei LM, et al. Climacteric. 2015;18(4):518-22. doi: 10.3109/13697137.2015.1020482. Epub 2015 Apr 1. Climacteric. 2015. PMID: 25830529
METHODS: Thirty 250-day-old Wistar rats were castrated and 3 weeks later received one of the following treatments by gavage for 5 weeks: (1) estradiol benzoate; (2) estradiol benzoate + medroxyprogesterone acetate; (3) estradiol benzoate + norethisterone …
METHODS: Thirty 250-day-old Wistar rats were castrated and 3 weeks later received one of the following treatments by gavage for 5 weeks: (1) …
Norethindrone acetate and estradiol-induced endometrial hyperplasia.
Kurman RJ, Félix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Kurman RJ, et al. Obstet Gynecol. 2000 Sep;96(3):373-9. doi: 10.1016/s0029-7844(00)00944-3. Obstet Gynecol. 2000. PMID: 10960628 Free article. Clinical Trial.
OBJECTIVE: To identify the lowest effective continuous dose of norethindrone acetate that significantly reduces 12-month incidence of endometrial hyperplasia associated with unopposed 17beta-estradiol (E2), 1 mg. ...RESULTS: Continuous-combined E2-norethindrone …
OBJECTIVE: To identify the lowest effective continuous dose of norethindrone acetate that significantly reduces 12-month incidence of …
Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
Notelovitz M, Cassel D, Hille D, Furst KW, Dain MP, VandePol C, Skarinsky D. Notelovitz M, et al. Am J Obstet Gynecol. 2000 Jan;182(1 Pt 1):7-12. doi: 10.1016/s0002-9378(00)70483-2. Am J Obstet Gynecol. 2000. PMID: 10649149 Clinical Trial.
OBJECTIVE: This study was undertaken to evaluate the efficacy and tolerability of a combination estradiol plus norethindrone acetate transdermal delivery system given in a continuous sequential regimen with transdermal estradiol versus placebo in the treatmen …
OBJECTIVE: This study was undertaken to evaluate the efficacy and tolerability of a combination estradiol plus norethindrone a …
Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW, Gluck OS, Lang E, Rakov V. Greenwald MW, et al. Menopause. 2005 Nov-Dec;12(6):741-8. doi: 10.1097/01.gme.0000184425.73567.12. Epub 2005 Nov 8. Menopause. 2005. PMID: 16278618 Clinical Trial.
OBJECTIVE: A 2-year multicenter, double-blind, randomized, placebo-controlled study examined the efficacy and safety of different doses of 17beta-estradiol (E(2)) alone and continuous-combined oral formulations of E(2) and norethindrone acetate (NETA) versus placebo …
OBJECTIVE: A 2-year multicenter, double-blind, randomized, placebo-controlled study examined the efficacy and safety of different doses of 1 …
A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.
Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. Archer DF, et al. Obstet Gynecol. 1999 Oct;94(4):498-503. doi: 10.1016/s0029-7844(99)00359-2. Obstet Gynecol. 1999. PMID: 10511348 Clinical Trial.
OBJECTIVE: To determine whether a continuous estradiol-norethindrone acetate transdermal delivery system reduces incidence of endometrial hyperplasia in postmenopausal women more than transdermal estradiol (E2) alone. ...The E2-norethindrone acetate co …
OBJECTIVE: To determine whether a continuous estradiol-norethindrone acetate transdermal delivery system reduces incidence of …
A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
Adler G, Young D, Galant R, Quinn L, Witchger MS, Maki KC. Adler G, et al. Gynecol Obstet Invest. 2005;59(4):212-9. doi: 10.1159/000084346. Epub 2005 Mar 7. Gynecol Obstet Invest. 2005. PMID: 15753617 Clinical Trial.
AIM: This multicenter, open-label, single-arm study evaluated subject satisfaction and improvements in menopausal quality of life among menopausal women using the CombiPatch transdermal system consisting of 17beta-estradiol 0.05 mg plus norethindrone acetate 0.14 mg …
AIM: This multicenter, open-label, single-arm study evaluated subject satisfaction and improvements in menopausal quality of life among meno …
3,055 results